Acta Vet. Brno 2023, 92: 143-149

https://doi.org/10.2754/avb202392020143

Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer

Vladimír Tancoš1, Marcel Kovalik2, Martin Levkut3, Martina Bobrovská4, Petra Kolenčíková4, Ľubomír Straka5, Zuzana Ševčíková3, Ondřej Škor6, Martina Antošová7, Lukáš Plank4, Keith L. Thoday8

1Pavol Jozef Safarik University and Louis Pasteur University Hospital, Institute of Pathology, Košice, Slovak Republic
2Anima Group, s.r.o., Veterinary Hospital Anima Vets, Žilina, Slovak Republic
3University of Veterinary Medicine and Pharmacy, Department of Morphological Disciplines, Košice, Slovak Republic
4Comenius University Bratislava, Jessenius Faculty of Medicine, Department of Pathological Anatomy, Martin, Slovak Republic
5Unilabs Slovensko, s.r.o., Department of Pathological Anatomy, Prešov, Slovak Republic
6Laboklin GMBH & CO.KG, Labor für Klinische Diagnostik, Bad Kissingen, Germany
7University Hospital Martin, Department of Development and Strategic Investments, Martin, Slovak Republic
8The University of Edinburgh, The Royal (Dick) School of Veterinary Studies, Department of Veterinary Clinical Sciences, Easter Bush Veterinary Centre, Roslin, Midlothian, Scotland

Received January 23, 2023
Accepted May 4, 2023

References

1. Abadie J, Nguyen F, Loussouarn D, Peńa L, Gama A, Rieder N, Belousov A, Bemelmans I, Jaillardon L, Ibisch C, Campone M 2018: Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. Breast Cancer Res Treat 167: 459-468 <https://doi.org/10.1007/s10549-017-4542-8>
2. Ahn S, Woo JW, Lee K, Park SY 2020: HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 54: 34-44 <https://doi.org/10.4132/jptm.2019.11.03>
3. Alves WEFM, Bonatelli M, Dufloth R, Kerr LM, Carrara GFA, Alves da Costa RF, Neto CS, Tiezzi D, da Costa Vieira RA, Pinheiro C 2019: CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy. BMC Cancer 19: 1173 <https://doi.org/10.1186/s12885-019-6353-2>
4. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M 2007: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Brit J Cancer 96: 1504-1513 <https://doi.org/10.1038/sj.bjc.6603756>
5. Bartošová M, Parkkila S, Pohlodek K, Karttunen TJ, Galbavý Š, Mucha V, Harris AL, Pastorek J, Pastoreková S 2002: Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2: Carbonic anhydrase IX and c-erbB2 in breast cancer. J Pathol 197: 314-321 <https://doi.org/10.1002/path.1120>
6. Bergholtz H, Lien T, Lingaas F, Sřrlie T 2022: Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors. J Mammary Gland Biol Neoplasia 27: 171-183 <https://doi.org/10.1007/s10911-022-09523-9>
7. Bonacho T, Rodrigues F, Liberal J 2020: Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. Biotech Histochem 95: 71-91 <https://doi.org/10.1080/10520295.2019.1651901>
8. Brennan DJ, Jirstrom K, Kronblad Ĺ, Millikan RC, Landberg G, Duffy MJ, Rydén L, Gallagher WM, O’Brien SL 2006: CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12: 6421-6431 <https://doi.org/10.1158/1078-0432.CCR-06-0480>
9. Campos NSP, de Souza BS, Silva GCP, Porto VA, Chalbatani GM, Lagreca G, Janji B, Suarez ER 2022: Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy. Cancers 14: 1392 <https://doi.org/10.3390/cancers14061392>
10. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL 2001: Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19: 3660-3668 <https://doi.org/10.1200/JCO.2001.19.16.3660>
11. Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ 2021: Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel) 13: 4455 <https://doi.org/10.3390/cancers13174455>
12. Furjelová M, Kovalská M, Jurková K, Horáček J, Carbolová T, Adamkov M 2014: Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma. Acta Histochem 116: 89-93 <https://doi.org/10.1016/j.acthis.2013.05.009>
13. Furjelova M, Kovalska M, Jurkova K, Chylikova J, Mestanova V, Adamkov M 2015: Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer. Neoplasma 62: 88-97 <https://doi.org/10.4149/neo_2015_011>
14. Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL 2006: Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer 13: 921-930 <https://doi.org/10.1677/erc.1.01216>
15. Gloyeske NC, Woodard AH, Elishaev E, Yu J, Clark BZ, Dabbs DJ, Bhargava R 2015: Immunohistochemical profile of breast cancer with respect to estrogen receptor and HER2 status. Appl Immunohistochem Mol Morphol 23: 202-208 <https://doi.org/10.1097/PAI.0000000000000076>
16. Hussain S, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L, James ND, Spooner D, Poole CJ, Rea DW, Palmer DH 2007: Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Brit J Cancer 96: 104-109 <https://doi.org/10.1038/sj.bjc.6603530>
17. Ilardi G, Zambrano N, Merolla F, Siano M, Varricchio S, Vecchione M, Rosa G, Mascolo M, Staibano S 2014: Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers. Curr Med Chem 21: 1569-1582 <https://doi.org/10.2174/09298673113209990227>
18. Kim Sa, You D, Jeong Y, Yu J, Kim S, Nam S, Lee J 2018: TP53 upregulates α‑smooth muscle actin expression in tamoxifen‑resistant breast cancer cells. Oncol Rep 41: 1075-1082
19. Li, LT, Jiang G, Chen Q, Zheng JN 2015: Ki67 is a promising molecular target in the diagnosis of cancer (Review). Molecular Med Rep, 11: 1566-1572 <https://doi.org/10.3892/mmr.2014.2914>
20. Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC, Ostlund C, Aparicio S, Winum J-Y, Supuran CT, Dedhar S 2013: Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 32: 5210-5219 <https://doi.org/10.1038/onc.2012.550>
21. Mahon B, Pinard M, McKenna R 2015: Targeting carbonic anhydrase IX activity and expression. Molecules 20: 2323-2348 <https://doi.org/10.3390/molecules20022323>
22. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ 1999: The tumour suppressor protein VHLtargets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275 <https://doi.org/10.1038/20459>
23. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, Glass A, Zehnbauer BA, Lister K, Parwaresch R 2005: Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 18: 1067-1078 <https://doi.org/10.1038/modpathol.3800388>
24. Monti MS, Supuran CT, De Simone CG 2012: Carbonic anhydrase IX as a target for designing novel anticancer drugs. Curr Med Chem 19: 821-830 <https://doi.org/10.2174/092986712799034851>
25. Pastorek J, Pastorekova S 2015: Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Semin Cancer Biol 31: 52-64 <https://doi.org/10.1016/j.semcancer.2014.08.002>
26. Span PN, Bussink J, Manders P, Beex LVAM, Sweep CGJ 2003: Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Brit J Cancer 89: 271-276 <https://doi.org/10.1038/sj.bjc.6601122>
27. Sundaresan S, Penuel E, Sliwkowski MX 1999: The biology of human epidermal growth factor receptor 2. Curr Oncol Rep 1: 16-22 <https://doi.org/10.1007/s11912-999-0005-7>
28. van Kuijk SJA, Yaromina A, Houben R, Niemans R, Lambin P, Dubois LJ 2016: Prognostic significance of carbonic anhydrase IX expression in cancer patients: A meta-analysis. Front Oncol 6: 69 <https://doi.org/10.3389/fonc.2016.00069>
29. Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim S-B, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL 2021: Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. Clin Cancer Res 27: 6156-6163 <https://doi.org/10.1158/1078-0432.CCR-21-2103>
30. Watson P, Chia S, Wykoff C, Han C, Leek RD, Sly WS, Gatter KC, Ratcliffe P, Harris AL 2003: Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Brit J Cancer 88: 1065-1070 <https://doi.org/10.1038/sj.bjc.6600796>
31. Winum J-Y, Scozzafava A, Montero J-L, Supuran CT 2009: Inhibition of carbonic anhydrase IX: A new strategy against cancer. Anticancer Agents Med Chem 9: 693-702 <https://doi.org/10.2174/187152009788680028>
32. WHO Classification of Tumours Editorial Board 2019: Breast tumours. International Agency for Research, Lyon (France)
33. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF 2013: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31: 3997-4013 <https://doi.org/10.1200/JCO.2013.50.9984>
34. Yan H, Xiao H, Zhu J, Zhang J, Liu Z 2020: Association between the HER2 protein expression level and the efficacy of neoadjuvant chemotherapy in HER2-positive breast cancer. Cancer Manag Res 12: 12715-12722 <https://doi.org/10.2147/CMAR.S278694>
35. Yeh IT, Mies C 2008: Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med 132: 349-358 <https://doi.org/10.5858/2008-132-349-AOITBL>
36. Zaha DC 2014: Significance of immunohistochemistry in breast cancer. World J Clin Oncol 5: 382-392 <https://doi.org/10.5306/wjco.v5.i3.382>
front cover
  • ISSN 0001-7213 (printed)
  • ISSN 1801-7576 (electronic)

Current issue

Archive